Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

A user is considering switching from finasteride to dutasteride due to unsatisfactory results and is concerned about experiencing another shedding phase. Another user recently made the switch and will update on their experience.

The conversation discusses the potential availability and use of the pp405 molecule for hair loss treatment, with concerns about its legitimacy and safety on the grey market. Participants also mention using products from Umbrella Labs and discuss the concentration and production costs of pp405.

The user switched from oral finasteride to a combined sublingual troche with minoxidil and noticed hair thinning, questioning if the change in administration caused shedding. They plan to return to the original method after six months, considering the possibility of a normal hair phase or psychosomatic concerns.

Minoxidil increases blood supply to the scalp, strengthening dormant follicles and extending the growth phase, but may increase scalp activity that can be countered with DHT blockers. Women experiencing side effects from finasteride or dutasteride for hair loss might consider alternatives like estrogen, especially if on birth control.

The user has been using oral finasteride and minoxidil for 6 months and noticed increased hair shedding in the last 1-1.5 months. They are seeking advice on when the shedding phase might stop, as it has been concerning despite no significant change in hair density.

Oral minoxidil caused changes in hair texture, making it curly, dry, and lifeless, raising concerns about whether this is a temporary phase or permanent. Users discussed potential side effects of oral minoxidil, including heart issues, and suggested consulting a dermatologist and monitoring health markers.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

Placebo hair regrowth might be influenced by propylene glycol in lotions or participants lying about using other treatments like minoxidil, finasteride, or microneedling. Being part of a study can also improve hair health due to lifestyle changes.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

Finasteride can cause scalp itch and inflammation, possibly due to DHT changes, but these effects are often temporary and part of the shedding phase. Consistent use of finasteride may show results after 6 months, with potential hair regrowth and slowed hair loss.

The user experienced significant hair improvement using oral finasteride and minoxidil but is now facing a secondary hair shedding phase after nine months, possibly linked to weight loss or seasonal changes. Despite concerns, others in the conversation suggest that such shedding is normal and temporary.

A 25-year-old experienced hair regrowth and reduced shedding after 9 months on finasteride, with inconsistent minoxidil use. Users discussed hairline changes, shedding phases, and the effectiveness of finasteride, with some mentioning side effects and other treatments like rosemary oil.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

A 30-year-old male experienced hair shedding while using Minoxidil and Finasteride, with concerns about whether this is a normal shedding phase. Despite drastic hair loss, he continues the treatment, hoping for regrowth, and receives advice to maintain the regimen and consider lifestyle changes.

KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.

Pyrilutamide phase 3 results showed little to no significant hair regrowth, but may be sufficient for maintaining current hair density. The user is unsure due to lack of recent discussions on pyrilutamide.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

The user experienced significant hair recovery after 14 months using oral Propecia (finasteride) 1 mg daily and oral minoxidil, and recently added topical minoxidil and topical Propecia to their regimen. The doctor recommended this combination to maximize results, and the user reported no side effects, noticing improvements by the third month.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Topical dutasteride 0.05% is more effective for hair growth than oral finasteride 1mg, with minimal DHT reduction. The formulation uses castor oil and MCTs for better absorption but is not widely available until 2028.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

The "Big 3 Stack" for hair loss treatment, which includes Minoxidil for hair density improvement, Ketoconazole shampoo for enhancing hair volume and thickness, and Finasteride for blocking hair loss causing hormones. Microneedling can boost Minoxidil's effects.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

Kintor changed their KX-826 pictures on Amazon after backlash over fake images. Users are skeptical about the product's effectiveness and trustworthiness, with some preferring finasteride instead.

The new formulation includes minoxidil, finasteride, redensyl, caffeine, and propacil, and removes alcohol. The user is concerned about potential hair shedding due to the change in ingredients.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.